BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types

-The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs -BridgeBio and Helsinn have also established a non-exclusive framework agreement to identify and potentially co-develop and co-commercialize additional small molecule targeted oncology therapies -This framework agreement leverages BridgeBio’s drug discovery expertise […]

BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing

-Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Company’s 30+ genetic disease and cancer pipeline programs into 2024 PALO ALTO, Calif., NOVEMBER 18, 2021 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases […]

BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update

–Topline results from Part A of the Phase 3 ATTRibute-CM trial of TTR stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM) expected by end of 2021 –Meaningful progress in RAS cancer portfolio with discovery of next-generation KRAS G12C dual inhibitors and novel PI3ka:RAS breakers -Advancements in gene therapy pipeline with first patient dosed in Canavan disease trial and […]

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease

-If successful, BridgeBio’s gene therapy could be the first approved therapeutic option for children born with Canavan disease, a devastating and life-threatening condition -The Canavan disease program is part of BridgeBio’s growing gene therapy portfolio, which includes clinical candidates for congenital adrenal hyperplasia (CAH) and classic galactosemia (severe GALT deficiency), and preclinical programs for TMC1 […]

BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers

– The new agreements mean BridgeBio has collaborations with 25 leading academic institutions focused on genetic disease and precision oncology PALO ALTO, CA – October 29, 2021 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced two new academic collaborations with Columbia University and Mount Sinai (Icahn […]

BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

PALO ALTO, CA – October 25, 2021 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health’s efforts to promote diversity, […]

BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers

PALO ALTO, Calif., Oct. 12, 2021 /PRNewswire/ — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, is announcing meaningful progress in its KRAS cancer portfolio, new programs in gene therapy, and advancements in cardiorenal and early-stage Mendelian programs at its second annual R&D Day today. BridgeBio will also […]

BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small Cell Lung Cancer Models

-Preclinical findings that demonstrated efficacy in non-small cell lung cancer (NSCLC) driven by RAS or other MAPK-pathway activating mutations will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics -BridgeBio’s SHP2 inhibitor, BBP-398, is part of its growing precision oncology portfolio, which also includes KRAS inhibitors for KRAS cancers, GPX4 inhibitors […]

BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021

PALO ALTO, CA – October 6, 2021 – BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, today announced that it will host its second R&D Day on Tuesday, October 12, 2021, at 8:30 a.m. ET. BridgeBio founder and CEO Neil Kumar, Ph.D., will present and be joined by […]

BridgeBio Pharma Announces Updated Phase 2B Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants

– Data presented at American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting – Achieving simultaneous blood and urine calcium normalization is a challenge for patients with ADH1 due to the limitations of current standard-of-care – Encaleret could be the first approved therapy indicated specifically for the treatment of ADH1 if the development […]